Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
Authors' conclusion
Continuation of adalimumab monotherapy is an effective therapeutic option for the treatment of non-infectious uveitis in children who are intolerant to the combination of adalimumab and methotrexate or mycophenolate mofetil.
Study context
- Population
- Children with non-infectious uveitis on adalimumab monotherapy (August 2015 to June 2022) after intolerance to accompanying MTX or MMF56 eyes
- Participants
- 28 children
- Outcome
- Disease control: proportion with less than a 2-step worsening in uveitis (SUN score) and no additional systemic immunosuppression during follow-up
- Follow-up
- During
Main finding
As reported in the abstract
Disease control on adalimumab monotherapy: <2-step worsening in uveitis (SUN score) and no additional systemic immunosuppression · During the study period
Study subjects who met the primary outcome
23
82.14%
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Values |
|---|---|
| Remission maintained (Kaplan-Meier) · 12 monthsKaplan-Meier survival analysis | Adalimumab monotherapy 81.25% (95% CI 60.6–91.7%) |
Original publication
Outcome of adalimumab monotherapy in paediatric non-infectious uveitis. Pediatr Rheumatol Online J. Published 2 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →